Biomarin Pharmaceutical Inc (BMRN)

Current ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Total current assets	US$ in thousands	2,985,010	2,956,090	2,955,310	2,950,120	2,842,100	2,751,460	2,682,700	2,517,600	2,394,020	2,274,380	2,311,570	2,357,840	2,288,770	2,342,220	2,738,980	2,647,570	2,116,250	1,942,140	1,859,360	1,806,770
Total current liabilities	US$ in thousands	1,087,900	1,177,020	1,163,220	597,231	598,231	588,884	521,020	464,727	490,418	546,497	514,898	443,344	430,035	492,548	854,693	813,302	820,470	932,503	493,745	439,428
Current ratio		2.74	2.51	2.54	4.94	4.75	4.67	5.15	5.42	4.88	4.16	4.49	5.32	5.32	4.76	3.20	3.26	2.58	2.08	3.77	4.11

March 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $2,985,010K ÷ $1,087,900K
= 2.74

The current ratio of Biomarin Pharmaceutical Inc has exhibited some fluctuations over the past several quarters. As of March 31, 2024, the current ratio stands at 2.74, indicating that the company has $2.74 in current assets for every $1 in current liabilities. This reflects an improvement from the previous quarter, where the current ratio was 2.51.

Looking further back, the current ratio has generally remained above 2, indicating that Biomarin Pharmaceutical Inc has a strong ability to cover its short-term obligations with its current assets. The peak current ratio of 5.42 in June 30, 2022, suggests a particularly strong liquidity position at that time.

However, it's important to note that the current ratio dropped significantly in the most recent quarter compared to the peak levels seen in 2022. A current ratio of 2.74 is still considered healthy, but investors and analysts may want to monitor future trends to ensure the company maintains a sufficient level of liquidity to meet its short-term obligations.